Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

Launched by UNIVERSITY OF CALIFORNIA, DAVIS · Sep 4, 2014

Keywords

ClinConnect Summary

This clinical trial is studying how well the pneumococcal vaccine works in patients who have suffered an injury to their spleen. People without a spleen are more vulnerable to serious infections, particularly from a type of bacteria called pneumococcus. The researchers want to see how the vaccine triggers an immune response in patients who are treated for their spleen injury in different ways, such as through surgery or other procedures.

The trial is open to adult trauma patients aged 18 to 65 who have a spleen injury. Unfortunately, those younger than 18 or older than 65 cannot participate. If someone starts with a non-surgical treatment but later needs surgery to remove the spleen, they will be taken out of the study. Participants will receive the vaccine and be monitored to see how their bodies respond. This research is important because it may help improve vaccine effectiveness and protection for patients at risk of infections after spleen injuries.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult trauma patients (aged 18 to 65 years old) sustaining a splenic injury.
• Exclusion Criteria:
• • Ages less than 18 and greater than 65
• • Initial planned nonoperative management patient who subsequently undergoes embolization or splenectomy will be withdrawn from the study.